Category: Accesswire

Athena will meet with industry stakeholders to explore affiliate partnerships, strategic partner opportunities, and deployment and expansion discussions

MIAMI, FL / ACCESS Newswire / February 5, 2026 / Athena Bitcoin Global (OTC PINK:ABIT)(“Athena” or the “Company”) announced today it will attend the ATMIA US Conference 2026, taking place February 10-12, 2026 at the Loews Arlington Hotel in Arlington, Texas. Athena Bitcoin’s Shane Miller will be onsite and available for partner meetings throughout the conference.

The ATMIA US Conference brings together experts across financial institutions, independent operators, and technology providers to explore key advancements shaping the ATM landscape, including AI integration, security, and expanded ATM functionality.

While onsite, Shane Miller will be meeting with attendees and prospective partners to discuss:

• Affiliate partnerships

• Strategic partner opportunities

• Deployment and expansion initiatives

“Athena’s priority is to help modernize cash access with a secure, compliant, and user-friendly experience,” said Shane Miller. “ATMIA is a strong forum to connect with operators and technology partners who are shaping what’s next for the ATM ecosystem, especially as AI and security requirements accelerate.”

During the event, Athena Bitcoin will connect with ecosystem stakeholders to align on collaboration opportunities, expansion plans, and best practices for delivering secure, scalable access experiences for end users.

About Athena Bitcoin Global

Athena Bitcoin Global operates an international network of Athena Bitcoin kiosks, which are freestanding kiosks that permit customers to buy or sell Bitcoin in exchange for fiat currencies. The Company places its machines in convenience stores, shopping centers, and other easily accessible locations in thirty-five U.S. states and territories, and in four countries in Central and South America. Athena Bitcoin Global’s comprehensive fintech platform enables POS merchant payments powered by Athena Pay, and the Company provides safe, reliable, and personalized trading services through its Athena Plus services.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to various factors, including market conditions, regulatory developments, and organizational priorities.

Contact:

Rachele Andrejczak
Director of Global Marketing, Athena Bitcoin Global
rachele@athenabitcoin.com
(786) 347-6242

SOURCE: Athena Bitcoin Global

View the original press release on ACCESS Newswire

ESTERO, FL / ACCESS Newswire / February 5, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), wholly owned subsidiary, Buzz Bomb Caffeine Company, a marketer of a proprietary sublingual caffeine supplement today announced its participation at The Sports & Active Nutrition Summit USA, scheduled for February 18-20 in San Diego, CA. Aspire will feature its flagship caffeine product, BUZZ BOMB™, at the event.

The Sports & Active Nutrition Summit USA is a premier industry gathering that unites leaders in sports nutrition and active lifestyle innovation. The summit explores the intersection of scientific research, ingredient development, business strategy, and consumer trends through expert-led presentations, startup showcases, wellness programs, and extensive networking opportunities, helping attendees stay ahead in the evolving market of performance-oriented nutrition. The summit presents opportunities for networking and marketing to retailers of innovative products like BUZZ BOMB™

The participation of Buzz Bomb Caffeine Company at the Summit follows the recent launch of the redesigned BUZZ BOMB™ website, https://buzzbombcaffeine.com, which offers a seamless, mobile-optimized, and user-friendly experience. This digital enhancement is complemented by refreshed product branding, including a new logo and modern packaging designed to better reflect the product’s innovative capabilities.

BUZZ BOMB™ Caffeine and Sublingual Delivery
Unlike traditional energy drinks or pills, BUZZ BOMB™ utilizes a proprietary sublingual format delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method delivers pure caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.

BUZZ BOMB™ features 50mg of caffeine and is currently offered in four flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise serving of caffeine in easy-to-use single serving stick packs.

“The Sports & Active Nutrition Summit provides an excellent platform to demonstrate the rapid onset and convenience of our sublingual caffeine compared to conventional caffeine formats like sodas and energy drinks,” said Kraig Higginson, Interim CEO of Aspire. “We look forward to connecting with industry innovators and showcasing how BUZZ BOMB™ is poised to disrupt the active sports and fitness supplement market.”

JOIN US!

Date: February 18-20, 2026
Location: San Diego, CA

Join us in San Diego from February 18-20 for three days of innovative insights, industry networking, and discussions shaping the future of sports and active nutrition.

Visit us at the show for BUZZ BOMB™ samples, insightful conversations, and a chance to connect directly with our team.

To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com.

BUZZ BOMB™ Variety Pack

About The Sports & Active Nutrition Summit Series
The Sports & Active Nutrition Summit Series brings together industry professionals to bridge the gaps between cutting-edge science, business strategy, and key regulatory developments. It offers a one-stop shop for the latest must-have insights into the worlds of sports and active nutrition. The three-day interactive summit takes place annually in Europe and the US. To learn more, visit the event website at https://sportsnutritionsummit-usa.com/live/en/page/home

About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a sublingual delivery method that can deliver supplements to the body rapidly and precisely.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

The funding backs continued innovation in production-grade forecasting, anomaly detection, and artificial intelligence.

SAN FRANCISCO, CA / ACCESS Newswire / February 5, 2026 / Nixtla, the company building a foundation model purpose-built for time series forecasting, today announced it has raised $16 million in Series A funding. The round was led by Energize Capital, with participation from True Ventures and GreatPoint Ventures.

Founded four years ago, Nixtla was built to tackle the cost, unreliability, and operational burden of time series forecasting. While accurate forecasts underpin core decisions across nearly every industry, most forecasting systems remain resource-intensive to develop and challenging to maintain at scale. To solve this, the company has applied the same class of algorithms transforming language and vision to time-based data, unlocking insights that help organizations reduce uncertainty and plan more effectively.

Today, Nixtla has evolved from an open-source library with over 45 million downloads into a leading time series intelligence platform used by startups and Fortune 500 companies alike, including Microsoft, Zalando and Decathlon. Its enterprise-grade tools enable teams to generate up to 42% more accurate forecasts, detect anomalies, and achieve 10 times better inference efficiency compared to traditional forecasting methods.

“This Series A allows us to accelerate what matters most, building production-ready systems that solve real forecasting and decision-making problems,” said Max Mergenthaler Canseco, co-founder and CEO at Nixtla. “We’re growing our team with experienced engineers and researchers, investing deeper in product innovation, and continuing to build in the open alongside the practitioners who use our tools every day.”

Nixtla’s platform has already delivered proven results across demand planning, inventory, energy forecasting, logistics, and more, including a 35% increase in store-level forecast accuracy at a leading retail brand and an 85% reduction in forecasting false alerts at a top mobility company. As adoption accelerates, Nixtla’s TimeGPT has become an industry standard and preferred skill on job descriptions for new hires at companies like OpenAI, DoorDash, and Tesla.

The company’s products range from the Nixtlaverse , an open-source library with over 15,000 GitHub stars, to TimeGPT, the first production-ready foundation model for time series forecasting. Recent releases, including TimeGPT-2.1 and Nixtla Enterprise 2.0, introduce multivariate modeling and agentic forecasting capabilities as well. Nixtla has earned top ratings on G2 for Time Series Forecasting and Predictive Analytics, with strong marks for ease of use, value, and return on investment.

“Time series data sits at the center of energy and industrial operations,” said Juan Muldoon, Partner at Energize Capital and member of Nixtla’s board of directors. “The Nixtla team is transforming how organizations can use that data, from improving battery deployment schedules to anticipating supply chain interruptions. We’re excited to partner with the Nixtla team as they scale this foundational capability to build a stronger, more resilient economy.”

This new funding will enable Nixtla to strengthen and scale its production-grade models across enterprise and open-source platforms. To support this expansion, the company is actively hiring across engineering, product, and sales. Learn more about open roles and join the team, by visiting: https://www.nixtla.io/company

ABOUT NIXTLA:
Nixtla is a time series intelligence company building forecasting and anomaly detection tools for modern data teams. Through a combination of open-source libraries and enterprise-grade platforms, Nixtla helps organizations turn time-based data into actionable insight, enabling better planning and decision-making at scale. Learn more at https://www.nixtla.io/.

ABOUT ENERGIZE CAPITAL:
Energize Capital is a leading investor in climate solutions. Established in 2016 and based in Chicago, Energize seeks to scale sustainable innovation by partnering with the builders and operators shaping the future. To date, Energize has funded 39 companies and deployed more than $970 million through its Venture and Endurance strategies. Founded in partnership with Invenergy, the firm is backed by strategic, institutional, and impact LPs including Första AP-Fonden (AP1), GE Vernova, Capricorn, CDPQ, Builders Vision, UBS, WEC, Reference Capital, Keeling Capital, Keysight Technologies, WEX Venture Capital, and more. For more information on Energize, please visit www.energizecap.com.

MEDIA CONTACT: Lauren Gill, MAG PR at lauren@mooringadvisorygroup.com

SOURCE: Nixtla

View the original press release on ACCESS Newswire

VANCOUVER, BC AND BREDA, THE NETHERLANDS / ACCESS Newswire / February 5, 2026 / Organto Foods Incorporated (TSX-V:OGO)(OTCQX:OGOFF)(FSE:OGF0) (“Organto” or the “Company”) reports strong commercial momentum entering 2026, supported by new retail customer wins, expanded grower partnerships, and favorable long-term organic market trends across Europe.

During recent commercial negotiations and customer onboarding, Organto added 8 new retail customers to its existing portfolio. Several of these customers rank among the largest retailers in their respective markets, underscoring growing confidence in Organto’s ability to reliably supply high-quality organic produce at scale. These new commercial relationships extend the Company’s reach into three additional countries – Switzerland, Ukraine, and Spain – further strengthening Organto’s European platform and international footprint.

Supporting this commercial expansion, Organto has also broadened its supply partner network, securing six new growing partners across key sourcing regions. These additions enhance supply continuity for existing customers, support anticipated volume growth from new retail programs, and further strengthen the Company’s ability to deliver year-round organic produce with the quality, traceability, and reliability required by large-scale retailers.

Europe continues to represent one of the world’s most attractive and resilient markets for organic food. In 2023, retail sales of organic food in Europe reached approximately €54.7 billion, representing year-over-year growth of roughly 3%, with particularly strong demand across markets such as Germany, France, Switzerland, and the Nordic region. European consumers now spend an average of approximately €66 per person annually on organic food, with per capita spending in countries such as Switzerland and Denmark among the highest globally. Industry analysts project that the European organic food market could nearly double in size by 2033, reaching close to €132 billion in annual sales, driven by sustained consumer demand for healthy, sustainable, and traceable food products.¹

“The combination of new retail customer wins and an expanded grower base provide a strong foundation for our 2026 growth expectations,” said Steve Bromley, CEO of Organto Foods Inc. “Organic produce is no longer a niche category – it’s a structural shift in how consumers shop for food. Our platform is increasingly aligned with the needs of major retailers operating in one of the world’s most dynamic organic markets.”

As its scale grows across sourcing, logistics, and distribution, Organto is also evaluating opportunities to introduce additional organic product categories into its European retail programs. This next phase of expansion is expected to leverage the Company’s existing infrastructure and deepening retail relationships, supporting incremental growth while enhancing value for customers.

The organic produce category continues to benefit from long-term structural tailwinds, including strong consumer preferences for sustainability, ongoing investment in organic farming and certification, and supportive regulatory frameworks across Europe. Organto’s integrated model – combining strong retailer relationships, a diversified grower base, and an increasingly efficient logistics platform – positions the Company well to capitalize on these trends. With new customers onboarded, additional markets opened, expanded supply partnerships in place, and new category opportunities under review, Organto Foods Inc. enters 2026 well-positioned to execute its growth strategy and deliver long-term value across the organic supply chain.

Grant of Stock Options and Restricted Share Units

The Company also announces that it has granted 2,550,000 stock options exercisable to acquire up to 2,550,000 common shares of the Company at an exercise price of $0.85 per share until January 27, 2031, and 1,475,000 restricted share units to Directors, officers, and employees. The options were granted in accordance with the terms of the Company’s Share Option Plan. 675,000 of the options will vest as to 25% immediately and 25% every six months thereafter, and 1,875,000 of the options will vest as to 20% immediately and 20% every twelve months thereafter. The restricted share units were issued in accordance with the terms of the Company’s Restricted Share Unit Plan and will vest as to 50% vesting on the first anniversary of the date of grant and 25% each six months thereafter. The restricted share units have a term of three years.

¹ FiBL – Research Institute of Organic Agriculture, Media Release, February 11, 2025, “Almost 11 percent of agricultural land in the European Union is organically farmed.”

On Behalf of the Company

Steve Bromley

Co-Chair and CEO

Neither the TSX Venture Exchange nor its Regulatory Services Provider (as the term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this new release.

Investor & Media Contact:

John Rathwell
SVP, Corporate Development
john.rathwell@organto.com
www.organto.com

About Organto Foods

Organto Foods Inc. (TSX-V:OGO)(OTCQX:OGOFF)(FSE:OGF0) is a Canadian-headquartered company supplying certified organic and fairtrade produce to leading international retailers. Organto manages global sourcing, logistics and distribution through an integrated, capital-efficient model that connects growers and consumers with transparency, sustainability and operational excellence.

Forward Looking Statements

This news release may include certain forward-looking information and statements, as defined by law, including, without limitation, Canadian securities laws and the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). In particular, and without limitation, this news release contains forward-looking statements respecting Organto’s business model and markets; Organto’s belief that adding eight new retailers, six new growing partners and entering three new European countries will add significant momentum as the Company continues to accelerate its aggressive growth plans and strengthen its European platform and international footprint; Organto’s plans to evaluate opportunities to introduce additional organic product categories into existing retail programs; Organto’s belief that with new customers onboarded, additional markets opened, expanded supply partnerships in place, and new category opportunities under review, Organto enters 2026 well-positioned to execute its growth strategy and deliver long-term value across the organic supply chain; management’s beliefs, assumptions and expectations; the timing of the expected launch and duration of the marketing campaign to be facilitated by Machai; and general business and economic conditions. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including without limitation assumptions about the following: the ability and time frame within which Organto’s business model will be implemented and product supply will be increased; cost increases; dependence on suppliers, partners, and contractual counter-parties; changes in the business or prospects of Organto; unforeseen circumstances; risks associated with the organic produce business generally, including inclement weather, unfavorable growing conditions, low crop yields, variations in crop quality, spoilage, import and export laws, and similar risks; transportation costs and risks; general business and economic conditions; and ongoing relations with distributors, customers, employees, suppliers, consultants, contractors, and partners. The foregoing list is not exhaustive and Organto undertakes no obligation to update any of the foregoing except as required by law.

SOURCE: Organto Foods, Inc.

View the original press release on ACCESS Newswire

NEW YORK CITY, NEW YORK / ACCESS Newswire / February 5, 2026 / Stagwell (NASDAQ:STGW), the global challenger network transforming marketing through AI, today announced the appointment of Ben Berentson as CEO, Owned Media, effective immediately. Berentson will drive the operations, growth, and expansion of Stagwell’s owned media portfolio including Ink, ReachTV, RealClearPolitics, and future initiatives, advancing the portfolio as a strategic business engine for the global network.

Ben brings 20+ years of experience spanning corporate digital strategy and hands-on leadership of digital media businesses. He began his career at Forbes before joining Condé Nast, where he held senior corporate digital strategy roles and led digital at both Glamour and Vogue during periods of rapid expansion and innovation. Most recently, Ben served as Managing Director at Stagwell’s Code and Theory, Adweek’s Innovation Agency of the Year, where he led the business through a period of growth and transformation for nearly a decade.

“Berentson is a true professional with long-standing media experience, and his appointment will accelerate our push to scale differentiated media platforms with real market impact,” shared Stagwell Chairman and CEO Mark Penn. “By continuing to invest in and scale our owned media capabilities, we are doubling down on what sets us apart and fuels growth across the network.”

Berentson remarked on his new role: “Stagwell’s owned media platforms are a powerful differentiator, and I’m looking forward to scaling them even further. Building engagement and direct relationships with the highest-value audiences is a critical piece of our strategy, and industry disruption creates a clear opportunity to leverage Stagwell’s unique capabilities, strengthening how we show up in the market and unlocking new ways for brands to connect with audiences.”

About Stagwell

Stagwell is the global challenger network transforming marketing through AI. We deliver scaled creative performance for the world’s most ambitious brands, connecting culture-moving creativity with leading-edge technology to harmonize the art and science of marketing. Led by entrepreneurs, our specialists in 45+ countries are unified under a single purpose: to drive effectiveness and improve business results for our clients. Join us at www.stagwellglobal.com.

Media Contact

Maggie Axford
PR@stagwellglobal.com

SOURCE: Stagwell

View the original press release on ACCESS Newswire

Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms.

MIAMI, FLORIDA / ACCESS Newswire / February 5, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental biological mechanisms implicated in cancer, aging, and degenerative disease, today announced new cellular study results demonstrating that Telomir-1, in the form of Telomir-Zn, induces a rapid and coordinated intracellular redistribution of zinc and iron.

These findings extend Telomir’s previously reported intracellular iron-reduction data by directly demonstrating, for the first time, that Telomir-Zn simultaneously increases intracellular zinc while reducing redox-active ferrous iron inside living cells. The coupled nature of these effects supports a differentiated intracellular metal-modulating mechanism rather than simple extracellular metal chelation.

Why This Biology Matters in Cancer and Aging

Cancer and accelerated aging are increasingly understood to share common upstream biological drivers, including dysregulated metal homeostasis, excess oxidative stress, mitochondrial dysfunction, epigenetic instability, and cumulative genomic damage.

Redox-active metals such as iron and copper can catalyze the formation of reactive oxygen species (ROS), which, over time, contribute to mitochondrial damage, oxidative DNA lesions, disruption of DNA methylation patterns, and telomere attrition. These processes are closely associated with epigenetic drift, impaired DNA repair, and genomic instability-hallmarks observed across both tumor biology and age-associated cellular decline.

Zinc plays a distinct biological role. Unlike iron and copper, zinc is redox-inert under physiological conditions and supports chromatin structure, DNA repair, antioxidant defense systems, and telomere-associated genomic stability. Maintaining appropriate intracellular zinc availability while limiting excess redox-active metals is therefore central to preserving cellular function over time.

Study Overview and Key Findings

To assess whether Telomir-Zn alters intracellular metal pools, Telomir Pharmaceuticals, in collaboration with Smart Assays Biotechnologies, has quantified labile intracellular zinc and iron levels in cultured human HaCaT cells using complementary live-cell fluorescent probes.

Key observations include:

• Rapid, dose-dependent zinc accumulation: Telomir-Zn exposure resulted in a measurable increase in intracellular zinc within 30 minutes, sustained over a two-hour period at low-micromolar concentrations, without loss of cell confluence or viability.

• Reciprocal reduction of redox-active iron: Increasing Telomir-Zn concentrations were associated with progressive depletion of the intracellular ferrous iron pool, most closely linked to oxidative stress.

• Coordinated intracellular modulation: Zinc accumulation and iron reduction occurred over similar concentration ranges and timeframes, supporting a coordinated intracellular process rather than independent or nonspecific metal effects.

Mechanistic Interpretation: Linking Metals, Mitochondria, Epigenetics, and Telomeres

Excess intracellular iron and copper are known to impair mitochondrial respiration, amplify ROS generation, and disrupt metal-dependent enzymes that regulate chromatin structure and DNA methylation. Several histone demethylases and DNA repair enzymes require tightly regulated Fe²⁺ availability, and metal imbalance can destabilize epigenetic control systems and accelerate genomic stress.

The observed Telomir-Zn-associated increase in intracellular zinc, coupled with a reduction of labile iron, is consistent with a proposed intracellular mechanism by which modulation of metal availability may attenuate oxidative stress while supporting zinc-dependent regulatory functions. These pathways are closely linked to mitochondrial health, epigenetic regulation, telomere maintenance, and long-term genomic stability, supporting the potential relevance of this mechanism across both oncology and age-associated disease biology.

Importantly, the epigenetically associated effects observed in these studies do not rely on inducing cellular damage or cytotoxic stress, distinguishing this approach from many existing epigenetic strategies that act through DNA damage or broad transcriptional disruption.

Management Commentary

“These findings link our earlier epigenetic and mitochondrial observations to a clear upstream mechanism-intracellular metal imbalance,” said Erez Aminov, CEO of Telomir Pharmaceuticals. “By simultaneously reducing redox-active iron while introducing protective zinc, Telomir-Zn appears to influence oxidative stress, DNA methylation, and genomic stability in a way that does not rely on cellular damage. We believe this approach has important implications for how cancer and age-related disease may be addressed at their biological roots.”

“For decades, cancer and age-related diseases have largely been approached by targeting downstream consequences-uncontrolled growth, accumulated damage, or end-stage dysfunction,” said Dr. Itzchak Angel, Chief Scientific Advisor at Telomir Pharmaceuticals. “What is emerging here is a different biological strategy: addressing upstream drivers such as oxidative stress, mitochondrial instability, and epigenetic drift that are shared across these conditions. By demonstrating for the first time that Telomir-Zn can simultaneously modulate intracellular zinc and iron-key regulators of DNA methylation, redox balance, and telomere-associated genomic stability-these findings support a framework that could fundamentally change how we think about intervening in cancer and aging biology, without relying on toxicity or cellular injury.”

Ongoing Activities and Upcoming Scientific Presentations

Telomir Pharmaceuticals plans to present data related to Telomir-Zn and its mechanism of action at several upcoming scientific and industry meetings, including:

• 16th World Congress on Breast Cancer Research & Therapies, March 23-24, 2026 (Paris, France)

• AACR Annual Meeting 2026, April 17-22, 2026 (San Diego, CA)

• BIO International Convention, June 22-25, 2026 (San Diego, CA)

• 3rd International Conference on Women’s Health and Breast Cancer, October 5-6, 2026 (Tokyo, Japan)

IND Preparation and Ongoing Research Activities

Telomir Pharmaceuticals is finalizing IND-enabling activities for Telomir-Zn, including assembly of the required data package to support regulatory submission. The Company currently plans to submit an Investigational New Drug (IND) application in the first quarter of 2026.

In parallel, Telomir continues to advance a portfolio of ongoing and completed preclinical research programs, including studies in triple-negative breast cancer (TNBC) models and longevity-focused models, evaluating the biological relevance of Telomir-Zn’s intracellular metal-modulating and epigenetically associated mechanisms.

Based on data generated from completed studies, manuscript submissions to peer-reviewed journals have been initiated, while additional data continue to be generated from ongoing preclinical studies. These efforts also support planned and upcoming scientific conference presentations.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The Company’s lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Krystina Quintana
Email: info@telomirpharma.com
Phone: (786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc

View the original press release on ACCESS Newswire

TORONTO, ONTARIO / ACCESS Newswire / February 5, 2026 / Electrovaya Inc. (Nasdaq:ELVA)(TSX:ELVA), a leading lithium-ion battery technology and manufacturing company, announces that it will file and release its first quarter ending December 31, 2025, following the market close on Thursday, February 12, 2026. This will be followed by a conference call and webcast at 5:00 p.m. EST on the same day, presented by CEO, Dr. Raj DasGupta and CFO, John Gibson to discuss the financial results and provide a business update.

Conference Call & Webcast details: 

• Date: Thursday, February 12, 2026

• Time: 5:00 pm. Eastern Time (ET)

• Toll Free: 888-506-0062

• International: 973-528-0011

• Participant Access Code: 824578

• Webcast link: https://www.webcaster5.com/Webcast/Page/2975/53605

To help ensure that the conference begins in a timely manner, please dial in 10 minutes prior to the start of the call. 

For those unable to participate in the conference call, a replay will be available for two weeks beginning on February 12, 2026, through February 26, 2026. To access the replay, the dial-in number is 877-481-4010 and 919-882-2331. The replay passcode is 53605.

Investor and Media Contact:     

Jason Roy
VP, Corporate Development and Investor Relations
Electrovaya Inc.
jroy@electrovaya.com / 905-855-4618

About Electrovaya Inc.

Electrovaya Inc. (NASDAQ:ELVA)(TSX:ELVA) is a technology-driven lithium-ion battery company commercializing its proprietary Infinity Battery Technology, designed for superior safety, longevity, and performance in mission-critical industrial, robotics, defense and energy-storage applications. The Company leverages a strong intellectual-property portfolio and advanced materials expertise to deliver durable, high-value battery solutions to global OEMs and end users. To support growing demand and advancing energy-security and national-security objectives, Electrovaya is expanding U.S. manufacturing through its 52-acre Jamestown, New York site, which includes a 137,000-square-foot facility planned as its first gigafactory. Electrovaya also operates two Canadian sites focused on research, engineering, and product commercialization. For more information, please visit www.electrovaya.com.

SOURCE: Electrovaya, Inc.

View the original press release on ACCESS Newswire

Twelve months of national and global coverage to include long-form interviews, earned media, television commercials, iconic outdoor billboards, and accredited investor events

NEW YORK CITY, NEW YORK / ACCESS Newswire / February 5, 2026 / Vivos Therapeutics, Inc. (NASDAQ:VVOS), a medical technology company focused on innovative solutions for breathing and sleep disorders, today announced that it has entered into a 12-part media series agreement with New to The Street, one of the longest-running business television and digital media platforms serving public companies in the U.S. and international markets.

The 12-month series is designed to expand Vivos Therapeutics’ visibility among investors, healthcare professionals, and strategic partners through a comprehensive, multi-channel media strategy spanning linear television, digital platforms, social media, outdoor advertising, and live investor engagement.

As part of the agreement, Vivos Therapeutics will receive:

Long-form broadcast interviews distributed nationally and internationally

Earned media coverage supporting corporate milestones and clinical positioning

Television commercials airing as sponsored programming alongside New to The Street broadcasts

Iconic outdoor billboard placements in high-impact financial and metropolitan locations

Accredited investor events, providing direct engagement with screened, invitation-only investor audiences

The series will allow Vivos Therapeutics to consistently communicate its clinical progress, commercial execution, and long-term growth strategy throughout the year.

“Partnering with New to The Street provides a sustained, credible platform to communicate our story to a broad audience of investors and stakeholders,” said a spokesperson for Vivos Therapeutics. “This multi-part series supports our commitment to education, transparency, and long-term shareholder engagement.”

The first segment in the Vivos Therapeutics series is expected to begin airing in the coming weeks, with coverage continuing throughout the 12-month term.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment solutions for breathing and sleep disorders arising from certain dentofacial abnormalities, including obstructive sleep apnea (OSA) and snoring in adults and children.

Vivos’ proprietary technologies have been cleared by the U.S. Food and Drug Administration (FDA) for use in adult patients diagnosed with all severity levels of OSA, as well as moderate-to-severe OSA in pediatric patients ages 6 to 17. The company’s groundbreaking Complete Airway Repositioning and Expansion (CARE) devices represent the only FDA 510(k)-cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate-to-severe OSA in children.

OSA affects more than one billion people worldwide, with an estimated 80% or more remaining undiagnosed. Beyond disrupted sleep, OSA is closely linked to numerous serious chronic health conditions. While legacy treatments such as CPAP have addressed symptoms, they are often mechanistic and may not address the underlying anatomical causes of the disorder.

Founded in 2016 and headquartered in Littleton, Colorado, Vivos is working to transform the standard of care for sleep-disordered breathing through innovative technology, education, and strategic collaborations with sleep healthcare providers. The company’s comprehensive approach-known as The Vivos Method-offers a proprietary, clinically effective, nonsurgical, noninvasive, and nonpharmaceutical solution, designed to address the root causes of OSA and improve long-term patient outcomes.

For more information, visit www.vivos.com.

About New to The Street

New to The Street is a 17-year-old, nationally and internationally syndicated business television brand that broadcasts weekly on Bloomberg Television as sponsored programming, featuring client interviews and television commercials. The program airs across the United States, MENA (Middle East & North Africa), and Latin America, delivering consistent global exposure.

In addition to its linear television distribution, New to The Street operates one of the largest YouTube subscriber channels in the financial and business media space, with over 4.4 million subscribers on New to The Street TV. The platform combines long-form interviews, earned media, digital amplification, and iconic outdoor advertising to deliver predictable, high-impact visibility for its clients.

https://youtube.com/@newtothestreettv

Media Contact:
Monica Brennan
New to The Street
Monica@NewtoTheStreet.com

SOURCE: New to The Street

View the original press release on ACCESS Newswire